Printer Friendly

BIORELEASE COMMENCES COMMERCIAL LAUNCH OF ERYTHROGEN; REPORTS INITIAL REVENUES AND PRODUCT SHIPMENTS OF THIS CELL CULTURE ADDITIVE

 SALEM, N.H., April 27 /PRNewswire/ -- Biorelease Corp. (NASDAQ: BREL) today announced the shipment of its first commercial order of Erythrogen(tm), a proprietary cell culture additive to promote cell growth, to a major cell culture media formulator. The company also announced the launch of a campaign to promote the product to the cell culture research community and industrial researchers at pharmaceutical companies.
 "These initial revenues represent an important milestone in our corporate history, as Biorelease evolves from a research organization into a company with product sales," said R. Bruce Reeves, Ph.D., chief operating officer of Biorelease. "Revenues generated from the sale of Erythrogen are expected to contribute initially to the company's development of additional cell culture additives, and later to the development of the pharmaceutical applications of our chondroitin sulfate technology."
 "Erythrogen has demonstrated the ability to enhance cell growth rates, density and viability, thereby indicating the potential for increased cell culture productivity," said Thomas J. Puskar, general manager and director of biotechnology. The company's two-tiered marketing strategy includes marketing Erythrogen as a proprietary product to the academic and industrial research communities, as well as sourcing the product on a bulk basis to leading cell culture supply companies to improve the efficiency of their existing cell culture media products.
 "One of the industry sectors targeted for Erythrogen is the insect cell culture market, which has been featured in biotechnology publications recently as a rapidly growing production method of choice. We believe the product may prove especially beneficial to cell culture research in this area," concluded Puskar.
 Biorelease Corp. is dedicated to commercializing proprietary cell-culture additives and developing pharmaceutical applications of its hemoglobin-based and chondroitin sulfate-based carrier technologies. The company is headquartered in Salem, N.H.
 -0- 4/27/93
 /CONTACT: R. Bruce Reeves, Ph.D., chief operating officer of Biorelease Corp., 603-893-7300; Marcia A. Kean, executive vice president or Chris Taylor, 617-577-8110, both of Feinstein Partners Inc., for Biorelease Corp./
 (BREL)


CO: Biorelease Corp. ST: New Hampshire IN: MTC SU: PDT

CH -- NE007 -- 1144 04/27/93 08:45 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 27, 1993
Words:342
Previous Article:ROBERT A. FEIN PROMOTED TO SENIOR VICE PRESIDENT, FINANCE FOR PERSEPTIVE BIOSYSTEMS
Next Article:EG&G FIRST QUARTER EARNINGS UP 6 PERCENT
Topics:


Related Articles
OIA, INC. CHANGES NAME TO BIORELEASE CORP.
BIORELEASE CORP. REPORTS FIRST QUARTER RESULTS
FORMER SENIOR DIRECTOR OF BRISTOL-MYERS SQUIBB APPOINTED V.P. PHARMACEUTICAL DEVELOPMENT & MEDICAL AFFAIRS AT BIORELEASE TECHNOLOGIES
BIORELEASE CORP. REPORTS SECOND FISCAL 1993 QUARTER RESULTS
BIORELEASE ESTABLISHES CELL CULTURE PRODUCTS DIVISION AND IS FINALIZING PLANS FOR COMMERCIAL LAUNCH OF ERYTHROGEN
BIORELEASE CORP. FILES REGISTRATION STATEMENT WITH SEC FOR STOCK OFFERING OF 160,000 UNITS OF COMMON STOCK (800,000 SHARES) AND WARRANTS
BIORELEASE CORP. NAMES DR. R. BRUCE REEVES CEO AND PRESIDENT
NOTED BLOOD SUBSTITUTE RESEARCHER JOINS BIORELEASE CORP.
BIORELEASE GRANTED TEMPORARY NASDAQ LISTING EXCEPTION
Biorelease Terminates Planned Merger with TheraMed, Names Gauci as President of BTI

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters